- Home
- IDYA vs LGND Comparison
IDYA vs LGND Comparison
Compare IDYA & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- LGND
- Stock Information
- Founded
- IDYA 2015
- LGND 1987
- Country
- IDYA United States
- LGND United States
- Employees
- IDYA N/A
- LGND N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- LGND Health Care
- Exchange
- IDYA Nasdaq
- LGND Nasdaq
- Market Cap
- IDYA 2.0B
- LGND 2.2B
- IPO Year
- IDYA 2019
- LGND 1992
- Fundamental
- Price
- IDYA $21.85
- LGND $120.67
- Analyst Decision
- IDYA Strong Buy
- LGND Strong Buy
- Analyst Count
- IDYA 13
- LGND 6
- Target Price
- IDYA $53.67
- LGND $145.00
- AVG Volume (30 Days)
- IDYA 972.2K
- LGND 81.8K
- Earning Date
- IDYA 02-13-2025
- LGND 02-27-2025
- Dividend Yield
- IDYA N/A
- LGND N/A
- EPS Growth
- IDYA N/A
- LGND 160.46
- EPS
- IDYA N/A
- LGND 2.47
- Revenue
- IDYA $7,000,000.00
- LGND $152,422,000.00
- Revenue This Year
- IDYA $111.81
- LGND $26.86
- Revenue Next Year
- IDYA $240.55
- LGND $14.95
- P/E Ratio
- IDYA N/A
- LGND $48.82
- Revenue Growth
- IDYA N/A
- LGND N/A
- 52 Week Low
- IDYA $19.96
- LGND $67.72
- 52 Week High
- IDYA $47.72
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- IDYA 43.52
- LGND 59.36
- Support Level
- IDYA $19.96
- LGND $110.42
- Resistance Level
- IDYA $21.65
- LGND $119.26
- Average True Range (ATR)
- IDYA 1.09
- LGND 3.82
- MACD
- IDYA -0.07
- LGND 0.61
- Stochastic Oscillator
- IDYA 33.57
- LGND 81.35
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.